M&A

News

Digital therapeutics firm Akili agrees $34 million takeover

In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeuti

News

Update: MSD confirms $3bn takeover of EyeBio

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular

News

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill

News

Asahi Kasei makes $1.1bn bid to buy Calliditas

Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to expand internationally in healthcare.

News

Biogen bets $1.15bn on immunology drug developer HI-Bio

Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range o

News

Merck builds in cell, gene therapies with Mirus Bio deal

Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a

Digital therapeutics firm Akili agrees $34 million takeover

Update: MSD confirms $3bn takeover of EyeBio

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

Asahi Kasei makes $1.1bn bid to buy Calliditas

Biogen bets $1.15bn on immunology drug developer HI-Bio

Merck builds in cell, gene therapies with Mirus Bio deal

Are Makary's priority review vouchers about to be canned?

Securing your ROI: Turning post-acquisition integration into...

M&A

Editor's Picks